Home / Countries / Germany

WHO European Region · country profile

HIV, PrEP and sexual health access in Germany

Germany: 92% of verified HIV medicine records are reimbursed; PrEP is available and reimbursed; sexuality education is classified as progressive. Compare medicines, prevention, reproductive rights and migrant healthcare access, with sources and the date each record was last checked.

Last checked 14/09/2026 · Sources cited on every record

Colour shows the share of verified HIV medicines that are reimbursed.

Read more: HIV medicines in GermanyPrEP in GermanyDoxyPEP in GermanySexuality education in GermanyAbortion and contraception rules in GermanyHealthcare for migrants in Germany

HIV medicines92% reimbursed24 of 26 verified recordsPrEPReimbursed40,000 PrEP recipients (2024; UNAIDS GAM)DoxyPEPAvailable, not reimbursedNational access and guidanceSexuality educationProgressivePolicy frameworkFamily planning & abortionProgressiveAbortion law and contraceptionMigrant healthcare accessWarningEntitlement and practice

16 HIV medicine records for Germany are still under review. They have not yet been checked against a national source and must not be read as confirmed access or non-access.

Are HIV medicines reimbursed in Germany?

Of 26 verified HIV medicine records for Germany, 24 are available and reimbursed (92%), 0 are available but not reimbursed and 2 are not available. 16 further records are still under review.

Reimbursed 24

Biktarvy, Celsentri, Delstrigo, Descovy, Dovato, Edurant, Generic TDF/FTC (Emtricitabine/Tenofovir DF), Genvoya, Intelence, Isentress, Juluca, Kaletra, Odefsey, Pifeltro and 10 more

Not available 2

Generic TLD (Tenofovir/Lamivudine/Dolutegravir), Generic TLE (Tenofovir/Lamivudine/Efavirenz)

See every medicine with its source ↓

Is PrEP available and reimbursed in Germany?

Yes. In SHAPE's review, PrEP is available and reimbursed in Germany.

PrEP recipients: 40,000 PrEP recipients (2024; UNAIDS GAM)

Statutory health insurance generally covers PrEP medication and related examinations for people at increased risk of HIV. [Source: https://gesund.bund.de/en/hiv-aids] UNAIDS GAM 2025 reports 40,000 people receiving PrEP in 2024. This is a service-use count, not a population coverage percentage, and it does not determine reimbursement. [Source: https://aidsinfo.unaids.org/dataset]

Is DoxyPEP available in Germany?

DoxyPEP can be accessed in Germany, but SHAPE's review did not find it reimbursed.

DoxyPEP is not approved for STI prevention and is limited to selected individual cases; preventive use must generally be paid by the patient. [Source: https://gesund.bund.de/sexuell-uebertragbare-infektionen-sti]

What is the policy on sexuality education in Germany?

SHAPE classifies the sexuality education framework in Germany as progressive. This describes the national policy framework, not how every school delivers it.

  • National framework: Sexuality education is compulsory under state education laws and curricula. Delivery differs by Land, but national standards generally include relationships, prevention and sexual diversity.
  • Interpretation: The status summarizes the verified policy framework; it does not guarantee uniform classroom delivery.

[Sources: https://www.unesco.org/gem-report/en/peer ; https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexuality-education ; https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFEN_ComprehensiveStudyReport_Online.pdf]

What are the rules on abortion and contraception in Germany?

SHAPE classifies family planning and abortion rights in Germany as progressive, combining abortion law and contraception policy.

  • Abortion: Abortion within 12 weeks after conception is exempt from punishment following state-approved counselling and a mandatory three-day waiting period; the Criminal Code framework remains in force.
  • Contraception: EPF's 2026 contraception-policy score is 78.6%; the atlas records no general coverage; targeted youth and regional support.
  • Interpretation: The status combines legal rules and national policy access; regional availability and individual eligibility may differ.

[Sources: https://abortion-policies.srhr.org/country/germany/ ; https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_2026_FEB22-HiRes.pdf]

Can migrants access healthcare in Germany?

SHAPE's editorial comparison places migrant healthcare access in Germany in the middle category (Warning). Entitlement: AsylbLG restricted benefits; analogous coverage after 36 months.

Provider type: Statutory/public providers / social authorities / NGO · International migrants (2024): 16,750,084

  • Access rule: Asylum applicants receive restricted benefits under the Asylum Seekers Benefits Act; analogous social-assistance coverage generally begins after 36 months, subject to statutory conditions.
  • Main barriers: Vouchers or local procedures, reduced early entitlements, language barriers and data-sharing fears can delay care for asylum seekers and undocumented people.
  • Migration measure: UN DESA estimates 16,750,084 international migrants at mid-year 2024. This is a point-in-time stock, not the number of people who arrived during 2024. The estimate is based on the foreign-born population. Refugee, asylum-seeker or refugee-like population data are incorporated where indicated by UN DESA.
  • Origin definition: The origin shares below use country or area of birth for foreign-born estimates and country of citizenship for foreign-citizen estimates. They do not establish a person's nationality, ethnicity, language, reason for migration, legal status, recent-arrival status or undocumented status.
  • Measurement basis: Foreign-born population + refugee/asylum adjustments (UN DESA code B R)
  • Evidence note: ECDC indicators use 2024 reports: the foreign-born share is calculated only among diagnoses with known origin; late diagnosis is the country-level share with CD4 <350 cells/µL and is not migrant-specific. Data Unavailable means no sufficiently interpretable value was published; a blank is not zero. The status is an editorial comparison of legal entitlement and practical access and does not apply equally to every migrant group.

Main origins: Poland (11.2%), Türkiye (9%), Ukraine (8.5%)

Selected HIV indicators: Foreign-born HIV Diagnoses (known origin, 2024): 58.3%; Late HIV Diagnosis (CD4 <350, 2024): 34.1%

Where can I get tested in Germany?

COMPASS lists 26 HIV and STI testing and counselling services in Germany, in Duisburg, Bochum, Bielefeld, Braunschweig, Kiel, Chemnitz and more.

See all services in Germany

How Germany compares

Germany ranks #2 of 53 countries with enough verified HIV medicine records, by share of records that are reimbursed (92%; median 82%).

0%Marker: median of all countries100%

Neighbouring and nearby countries

All HIV medicines in Germany

MedicineActive ingredientClassStatusEvidence and sourceChecked
Biktarvy
Gilead Sciences
Bictegravir / Emtricitabine / TAFINSTI + NRTI/NtRTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Celsentri
ViiV Healthcare
MaravirocEntry InhibitorReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Delstrigo
Merck
Doravirine / Lamivudine / Tenofovir DFNNRTI + NRTI/NtRTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Descovy
Gilead Sciences
Emtricitabine / TAFNRTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Dovato
ViiV Healthcare
Dolutegravir / LamivudineINSTI + NRTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Edurant
Janssen
RilpivirineNNRTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Generic TDF/FTC (Emtricitabine/Tenofovir DF)
Multiple (Generics)
Emtricitabine / Tenofovir DFNRTIReimbursedFully financed through the national health insurance framework. [Source: G-BA / RKI]14/09/2026
Genvoya
Gilead Sciences
Elvitegravir / Cobicistat / Emtricitabine / TAFINSTI + NRTI/NtRTI + pharmacokinetic enhancerReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Intelence
Janssen
EtravirineNNRTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Isentress
Merck
RaltegravirINSTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Juluca
ViiV Healthcare
Dolutegravir / RilpivirineINSTI + NNRTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Kaletra
AbbVie
Lopinavir / RitonavirPIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Odefsey
Gilead Sciences
Rilpivirine / Emtricitabine / TAFNNRTI + NRTI/NtRTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Pifeltro
Merck
DoravirineNNRTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Prezista
Janssen
DarunavirPIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Rekambys
Janssen
RilpivirineLong-Acting NNRTIReimbursedLong-acting injectable rilpivirine used with cabotegravir for maintenance treatment in eligible virologically suppressed patients. The existing Germany record for the complete Vocabria / Rekambys regimen is classified as 'Available and Reimbursed', so this required rilpivirine component uses the same access and reimbursement status. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]14/09/2026
Rukobia
ViiV Healthcare
FostemsavirAttachment InhibitorReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Sunlenca
Gilead Sciences
LenacapavirCapsid InhibitorReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Symtuza
Janssen
Darunavir / Cobicistat / Emtricitabine / TAFPI + NRTI/NtRTI + pharmacokinetic enhancerReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. EU regulatory update (as of 5 Oct 2026): on 25 June 2026 the CHMP adopted a positive opinion extending the indication, with a new 675/150/200/10 mg tablet strength, to adults and paediatric patients aged 6 years and older weighing at least 25 kg (previously adolescents aged 12 years and older weighing at least 40 kg). European Commission decision not confirmed during this review; national availability and reimbursement of the new strength not verified. [Sources: G-BA / RKI; https://www.ema.europa.eu/en/medicines/human/variation/symtuza]14/09/2026
Tivicay
ViiV Healthcare
DolutegravirINSTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Triumeq
ViiV Healthcare
Dolutegravir / Abacavir / LamivudineINSTI + NRTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Truvada
Gilead Sciences
Emtricitabine / Tenofovir DFNRTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. [Source: G-BA / RKI]14/09/2026
Vocabria
ViiV Healthcare
CabotegravirINSTIReimbursedFully reimbursed under statutory health insurance (GKV) with a specialist physician prescription. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: G-BA / RKI; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]14/09/2026
Vocabria / Rekambys
ViiV Healthcare / Janssen
Cabotegravir / RilpivirineLong-Acting ARTReimbursedEMA approved. Fully or partially reimbursed under the national health system for virologically suppressed patients. EU regulatory update (as of 5 Oct 2026): on 31 January 2025 the European Commission extended the authorisation of Vocabria plus Rekambys long-acting injections to virologically suppressed adolescents aged 12 years and older weighing at least 35 kg (adults authorised since December 2020). National reimbursement for adolescents not verified. [Sources: G-BA / RKI; https://www.pharmiweb.com/press-release/2025-01-31/european-commission-authorises-viiv-healthcare-s-long-acting-injectable-vocabria-plus-rekambys-for-hiv-treatment-in-adolescents-1; https://i-base.info/htb/50121]14/09/2026
Generic TLD (Tenofovir/Lamivudine/Dolutegravir)
Multiple (Generics)
Tenofovir DF / Lamivudine / DolutegravirINSTI + NRTI/NtRTINot availableGeneric combinations are typically not procured as branded single-tablet regimens are widely available. [Source: G-BA / RKI]14/09/2026
Generic TLE (Tenofovir/Lamivudine/Efavirenz)
Multiple (Generics)
Tenofovir DF / Lamivudine / EfavirenzNNRTI + NRTI/NtRTINot availableGeneric combinations are typically not procured as branded single-tablet regimens are widely available. [Source: G-BA / RKI]14/09/2026
Apretude
ViiV Healthcare
Cabotegravir (PrEP)INSTI (Long-Acting PrEP)Under reviewLong-acting injectable cabotegravir with oral lead-in tablets, for pre-exposure prophylaxis in adults and adolescents from 12 years weighing at least 35 kg. EMA confirms an EU/EEA-wide marketing authorisation granted by the European Commission on 19 September 2023. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/apretude]14/09/2026
Emtricitabine / Rilpivirine / Tenofovir Alafenamide Viatris
Viatris Limited
Emtricitabine / Rilpivirine / Tenofovir alafenamideNNRTI + NRTI/NtRTIUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 19 August 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilpivirine-tenofovir-alafenamide-viatris]14/09/2026
Emtricitabine / Tenofovir alafenamide Viatris
Viatris Limited
Emtricitabine / Tenofovir alafenamideNRTI/NtRTIUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 18 July 2025. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-tenofovir-alafenamide-viatris]14/09/2026
Emtriva
Gilead Sciences
EmtricitabineNRTIUnder reviewEmtricitabine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines for HIV-1 treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva]14/09/2026
Epivir
ViiV Healthcare
LamivudineNRTIUnder reviewLamivudine is a nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/epivir]14/09/2026
Eviplera
Gilead Sciences
Rilpivirine / Emtricitabine / Tenofovir DFNNRTI + NRTI/NtRTIUnder reviewA once-daily fixed-dose HIV-1 regimen containing rilpivirine, emtricitabine and tenofovir disoproxil; resistance history and viral-load restrictions apply. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera]14/09/2026
Evotaz
Bristol Myers Squibb
Atazanavir / CobicistatPI + pharmacokinetic enhancerUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 13 July 2015. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz]14/09/2026
Kivexa
ViiV Healthcare
Abacavir / LamivudineNRTIUnder reviewA fixed-dose NRTI backbone containing abacavir and lamivudine; HLA-B*5701 screening is required before abacavir treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa]14/09/2026
Norvir
AbbVie
RitonavirPI + pharmacokinetic enhancerUnder reviewRitonavir is a protease inhibitor used mainly at low dose as a pharmacokinetic enhancer for other protease inhibitors. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. EU regulatory update (as of 5 Oct 2026): on 18 September 2025 the CHMP adopted a positive opinion recommending changes to the existing indication and contraindications of Norvir, including guidance that when ritonavir is used as a pharmacokinetic enhancer the SmPC of the co-administered protease inhibitor should be consulted for contraindications. European Commission decision not confirmed during this review. [Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/norvir; https://www.ema.europa.eu/en/medicines/human/variation/norvir]14/09/2026
Retrovir
ViiV Healthcare
ZidovudineNRTIUnder reviewZidovudine is a nucleoside reverse transcriptase inhibitor used with other antiretroviral medicines; it is now generally a specialised or alternative treatment option. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir]14/09/2026
Reyataz
Bristol Myers Squibb
AtazanavirPIUnder reviewEMA confirms an EU/EEA-wide marketing authorisation issued on 2 March 2004. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz]14/09/2026
Rezolsta
Janssen
Darunavir / CobicistatPI + pharmacokinetic enhancerUnder reviewA fixed-dose combination of darunavir and cobicistat used with other antiretrovirals. EMA's CHMP issued a positive opinion on 25 June 2026 for a dispersible formulation and paediatric use from age 3 years and 15 kg. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta]14/09/2026
Stribild
Gilead Sciences
Elvitegravir / Cobicistat / Emtricitabine / Tenofovir DFINSTI + NRTI/NtRTI + pharmacokinetic enhancerUnder reviewA once-daily fixed-dose HIV-1 regimen containing an integrase inhibitor, pharmacokinetic enhancer and two reverse transcriptase inhibitors. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/stribild]14/09/2026
Viread
Gilead Sciences
Tenofovir DFNtRTIUnder reviewTenofovir disoproxil is a nucleotide reverse transcriptase inhibitor used with other antiretrovirals for HIV-1 treatment; renal and bone monitoring may be relevant. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/viread]14/09/2026
Yeytuo
Gilead Sciences
Lenacapavir (PrEP)Capsid Inhibitor (Long-Acting PrEP)Under reviewTwice-yearly injectable lenacapavir for pre-exposure prophylaxis; a separate marketing authorisation from Sunlenca, which covers treatment. The European Commission granted an EU/EEA-wide marketing authorisation on 26 August 2025 following accelerated EMA assessment. Country-level marketing, supply and reimbursement have not yet been verified. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo]14/09/2026
Ziagen
ViiV Healthcare
AbacavirNRTIUnder reviewAbacavir is a nucleoside reverse transcriptase inhibitor used in combination therapy; HLA-B*5701 screening is required before treatment. EMA confirms an EU/EEA-wide marketing authorisation. Product-specific national marketing, supply and reimbursement were not independently confirmed during this review; reimbursement status remains under review. [Source: https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen]14/09/2026

Sources

The evidence notes above quote these sources. Each record keeps its own source and last-checked date.

  • gesund.bund.de https://gesund.bund.de/en/hiv-aids
  • aidsinfo.unaids.org https://aidsinfo.unaids.org/dataset
  • gesund.bund.de https://gesund.bund.de/sexuell-uebertragbare-infektionen-sti
  • unesco.org https://www.unesco.org/gem-report/en/peer
  • who.int https://www.who.int/news-room/fact-sheets/detail/comprehensive-sexua…
  • bzga-whocc.de https://www.bzga-whocc.de/fileadmin/user_upload/Dokumente/BZgA_IPPFE…
  • abortion-policies.srhr.org https://abortion-policies.srhr.org/country/germany/
  • epfweb.org https://www.epfweb.org/sites/default/files/2026-02/CCInfoEU_A3_EN_20…
  • who.int https://www.who.int/europe/health-topics/refugee-and-migrant-health
  • ecdc.europa.eu https://www.ecdc.europa.eu/en/publications-data/hivaids-surveillance…
  • home-affairs.ec.europa.eu https://home-affairs.ec.europa.eu/policies/migration-and-asylum/asyl…
  • health.ec.europa.eu https://health.ec.europa.eu/social-determinants/migrants-health_en
  • gesetze-im-internet.de https://www.gesetze-im-internet.de/asylblg/__2.html
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/apretude
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-rilp…
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtricitabine-teno…
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/emtriva
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/epivir
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/eviplera
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/evotaz
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/kivexa
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/norvir
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/variation/norvir
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys
  • pharmiweb.com https://www.pharmiweb.com/press-release/2025-01-31/european-commissi…
  • i-base.info https://i-base.info/htb/50121
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/retrovir
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/reyataz
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/stribild
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/variation/symtuza
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/viread
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/yeytuo
  • ema.europa.eu https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen

Explore more

This page is for public information and policy discussion and is not medical or legal advice. Found an outdated record or a newer official source? Tell us.